Compare FRST & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | AVIR |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.2M | 450.9M |
| IPO Year | 2006 | 2020 |
| Metric | FRST | AVIR |
|---|---|---|
| Price | $13.25 | $5.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 85.8K | ★ 576.2K |
| Earning Date | 04-28-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 477.27 | 3.00 |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | $5.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $2.46 |
| 52 Week High | $14.55 | $6.45 |
| Indicator | FRST | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 51.33 |
| Support Level | $13.07 | $3.33 |
| Resistance Level | $14.42 | $6.45 |
| Average True Range (ATR) | 0.35 | 0.36 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 74.11 | 35.98 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.